NanoViricides, Inc., to Present at OneMedForum NY 2011 Trans-Atlantic Conference for Emerging Healthcare and Life Science Companies

2nd Annual Investment Conference to be held June 23-24, 2011, in New York City showcasing innovators in US and Europe

WEST HAVEN, CONNECTICUT -- June 22, 2011 -- NanoViricides, Inc. (OTC BB: NNVC) (the "Company"), a company that specializes in the development and commercialization of anti-viral drugs, has been invited to present at OneMedForum New York 2011 on June 23rd-24th, 2011 at The Roosevelt Hotel in New York City (

The sixth OneMedForum, the second in New York, continues to be a vital connecting point for healthcare/life science-focused emerging companies, business development executives and investors. This summer, the conference will focus on critical success factors for building companies on both sides of the Atlantic.

NanoViricides will use the opportunity to update investors on our current programs and activities, said Eugene Seymour, MD, MPH, CEO, who will give the presentation at the conference. The Company has recently announced that it is now arranging to have cGMP manufacturing capabilities in place for the future FDA filings. The Company has recently announced that its optimized FluCide™ drug candidates have shown dramatically high efficacies in animal models in all parameters tested. Three of the FluCide drug candidates demonstrated a lung viral load reduction of greater than 1,000-fold, in the same stringent lethal mouse model study where oseltamivir (Tamiflu®) exhibited less than 2-fold lung viral load reduction. The Company’s other programs, including HIVCide™, DengueCide™, HerpeCide™ skin cream, and an antiviral eye drops program are also progressing satisfactorily.

The OneMedForum Advisory Board, comprised of leading investors from both Europe and the US, work to identify companies with breakthrough technologies and innovative resolutions to long standing needs in the healthcare and life science industry.

About OneMedForum Founded in 2008, OneMedForum events are held biannually in San Francisco in January and in New York in June. They are designed to create a communications platform for emerging companies to connect with strategic partners and investors. OneMedForum New York was launched in 2010 which successfully brought together 74 promising private and microcap healthcare and life science companies with a wide range of investors and strategic partners.

About NanoViricides : NanoViricides, Inc. ( is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.  Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

NanoViricides, Inc.
Amanda Schuon, 310-550-7200